Peptide-related anxiety claims should be evaluated with the same care as other mental-health interventions. A proposed effect on neurotransmission or a positive personal report is not enough to establish a dependable treatment benefit.

A published Selank study compared 30 patients receiving Selank with 32 receiving medazepam in generalized anxiety disorder and neurasthenia. The abstract reported similar anxiolytic effects, but does not provide the detail needed to treat this as definitive evidence of equivalence or a broadly established treatment. Selank comparison in generalized anxiety disorder and neurasthenia

A small comparison has important limits

Without a suitable placebo comparison and clear information about blinding, assignment, prespecified outcomes and follow-up, several explanations can remain possible. Improvement can reflect expectation, natural fluctuation or other care. Similar observed outcomes do not automatically demonstrate statistical equivalence.

The population also matters. A study involving diagnosed disorders does not establish a general stress-resilience or cognitive-enhancement effect in healthy people. Long-term safety and the quality of a different commercial preparation are separate questions.

FDA’s warning concerns compounded drugs containing Selank acetate (TP-7): for certain administration routes, aggregation and peptide-related impurities may create immunogenicity risks. FDA also identifies important gaps in human safety information for Selank acetate. This assessment should not be generalized to every preparation called Selank or presented as proof that the clinical study formulation caused those harms. FDA safety concerns for nominated compounding substances

Established care remains available

NIMH describes psychotherapy, medication or both as treatment approaches for generalized anxiety disorder, with choices guided by the person’s needs and a qualified professional. Experimental peptide claims should not delay assessment or replace care without medical advice. NIMH generalized anxiety disorder information

AXON’s conclusion is that small studies can justify better research while leaving practical treatment questions unresolved. The appropriate next evidence would involve transparent methods, meaningful outcomes and adequate follow-up. This article does not recommend Selank, a nasal preparation or a self-directed anxiety protocol.